Findings
Home use devices face unique environmental challenges, including power interruptions, fluid exposure, and travel-related conditions.
Lay users often have limited training and varying physical, cognitive, and emotional capabilities, requiring user-friendly designs and clear instructions.
Effective risk management should include designing risks out of the device wherever possible, supplemented by protective measures and labeling as needed.
Verification, validation, and human factors testing are essential to confirm device performance and usability under realistic home-use scenarios.
Postmarket considerations, such as customer service and Medical Device Reporting (MDR), are vital for maintaining device safety and compliance.

Recommendations
Design devices for diverse environmental conditions, such as variable power supplies, fluid exposure, and extreme temperatures.
Include safeguards like lock-out mechanisms, robust alarm systems, and protective casings to mitigate risks.
Develop user-friendly labeling and instructions, employing narrative formats and visuals to address low literacy or technical proficiency.
Conduct human factors engineering and usability testing to identify and resolve potential design issues, ensuring safe device operation by lay users.
Plan for postmarket support, including accessible customer service and robust systems for adverse event reporting.

Regulatory Considerations
Premarket submissions should document efforts to address environmental and user-related risks, supported by verification, validation, and usability data.
Devices requiring electrical power must meet applicable ANSI/AAMI standards for safety, including those related to electromagnetic compatibility.
Manufacturers must comply with labeling requirements under 21 CFR Parts 801 and 809, ensuring clear communication of warnings, instructions, and limitations.
FDA emphasizes the use of recognized consensus standards, such as IEC 62304 for software lifecycle processes and ANSI/AAMI HE75 for human factors engineering.
Devices must incorporate mechanisms for handling emergencies, including power outages, and provide clear labeling on disposal, maintenance, and troubleshooting.

Findings:
Challenges in ensuring audit trail visibility for FDA inspections.
Risks of transcription errors when converting paper records into eCRFs.
Limited integration and standardization across electronic health record systems.
Potential security vulnerabilities in electronic signatures and data transmission.
Lack of comprehensive data quality checks in eCRF systems.

Recommendations:
Ensure the use of robust audit trails to track all changes and modifications to electronic source data.
Develop data management plans outlining roles, responsibilities, and data flow processes.
Use automated data capture methods (e.g., direct device transmission to eCRFs) to minimize errors.
Train clinical investigators and staff on maintaining accurate records and using eCRF systems.
Establish clear protocols for managing and retaining source data for FDA inspections.

Regulatory Considerations:
Compliance with FDA Part 11 regulations on electronic records and electronic signatures.
Retention of original or certified copies of source documents for FDA review.
Access control measures, such as unique logins and passwords, for eCRF systems.
Adherence to data traceability requirements, including data element identifiers.
Use of secure and interoperable systems for transmitting data to the eCRF.

Findings
RF wireless technologies in medical devices must account for crowded RF environments, coexistence issues, and risks associated with data loss, interference, and security breaches.
The quality of wireless signals (QoS) is critical for devices with time-sensitive or critical functionalities, such as alarms and life-support systems.
Electromagnetic compatibility (EMC) testing must address both emissions and immunity, ensuring devices can operate safely in shared RF environments.
Device labeling must inform users about potential interference, wireless security measures, and operating limitations in specific environments.
Postmarket risk management must address failure trends related to RF wireless performance, incorporating corrective and preventive actions to maintain safety.

Recommendations
Design Considerations: Use risk management practices to evaluate wireless technologies and determine appropriate risk mitigation strategies.
Limit RF output power to the minimum necessary to ensure functionality and reduce interference risks.
Testing and Validation: Conduct coexistence testing to evaluate performance in environments with other RF systems.
Perform EMC immunity testing under real-world operating conditions.
Security Measures: Implement encryption and authentication protocols to protect against unauthorized access.
Disable automatic connection modes (e.g., Bluetooth™ discovery) for safety-critical applications.
Premarket Submissions: Include a detailed description of the device’s wireless functions, risk mitigations, and testing protocols.
Summarize test results, including coexistence, EMC, and security assessments.
Labeling and User Instructions: Provide clear guidance on device setup, operation, and troubleshooting.
Include warnings about potential RF interference and instructions for maintaining signal quality and security.

Regulatory Considerations
Premarket submissions must include a description of the wireless technology, its intended use, and test data demonstrating compliance with standards.
EMC testing must conform to recognized consensus standards, such as IEC 60601-1-2, with modifications to address wireless technology.
FDA requires labeling to include information on operating frequencies, effective radiated power, and mitigation strategies for coexistence and security.
Postmarket risk management must analyze failure trends and implement corrective actions to address RF-related performance issues.
Compliance with Federal Communications Commission (FCC) regulations, including frequency band allocation and RF emission limits, is mandatory.

Findings
PRO instruments must demonstrate content validity through patient input and qualitative research, ensuring the instrument measures concepts relevant to the population and condition being studied.
Sponsors must confirm the reliability, construct validity, and ability to detect change for the PRO instrument before use in confirmatory clinical trials.
Statistical analysis plans should address multiplicity, handling of missing data, and cumulative distribution function comparisons to interpret clinical trial results.
Modifications to PRO instruments (e.g., format changes, population adaptations) require evidence that measurement properties are preserved.
Electronic PRO systems must comply with regulatory requirements for data integrity, security, and investigator access.

Recommendations
Develop and validate PRO instruments early in the clinical development process, ensuring alignment with the clinical trial’s endpoint model.
Document all stages of instrument development, including qualitative input from patients, pilot testing, and cognitive interviews.
Use clear and consistent administration procedures, whether paper-based or electronic, to minimize variability and missing data.
Define responder thresholds using anchor-based methods and consider presenting cumulative distribution functions to interpret treatment benefits.
Address cultural and linguistic adaptation of PRO instruments by ensuring equivalent content validity and measurement properties across versions.

Regulatory Considerations
Include detailed descriptions of the PRO instrument, its conceptual framework, and scoring algorithms in regulatory submissions.
Ensure PRO instruments used in clinical trials comply with FDA requirements for record-keeping, data security, and source data accessibility.
Plan for the FDA to review all modifications to PRO instruments, including changes in administration mode or population.
Address missing data in clinical trial protocols and statistical analysis plans, ensuring prespecified handling rules.
Provide evidence that PRO instruments reliably measure the intended concepts across all study populations and data collection methods.

Findings
Changes affecting the safety or effectiveness of a device typically require PMA supplements, categorized based on the nature of the change and required data.
Substantial changes (e.g., new indications or significant design modifications) may require a panel-track supplement or traditional PMA.
Minor modifications (e.g., certain design changes or labeling updates) can often be addressed with 180-day or real-time supplements.
Manufacturing changes impacting safety or effectiveness may be submitted as a 30-day notice or manufacturing site change supplement.
Risk analysis and assessment are critical in determining the appropriate regulatory pathway.

Recommendations
Conduct a thorough risk analysis for all modifications to assess potential impacts on safety and effectiveness.
For substantial design or performance changes, submit a panel-track supplement or traditional PMA, supported by substantial clinical data.
Use 180-day supplements for significant but less extensive changes, supported primarily by preclinical data or limited clinical testing.
Minor changes, such as software updates or sterilization changes, may qualify for real-time supplements if they can be evaluated within a single scientific discipline.
Submit minor manufacturing changes via 30-day notices or annual reports, ensuring all supporting documentation is complete.

Regulatory Considerations
Major modifications requiring new clinical data typically fall under panel-track supplements or traditional PMAs.
Manufacturing changes affecting safety and effectiveness must comply with 21 CFR 814.39 and can be submitted via 30-day notices or 180-day supplements.
Real-time supplements are limited to minor changes and require FDA pre-approval for expedited review.
Annual reports should include minor updates that do not impact device safety or effectiveness, as outlined in the guidance.
Manufacturing site changes are considered 180-day supplements and may involve pre-approval inspections depending on the nature of the change.

Findings
Emphasizes the importance of DMCs in enhancing trial participant safety.
Highlights the need for DMC independence to prevent bias.
Discusses the historical context and evolution of DMCs in clinical trials.
Notes that not all trials require a formal DMC.

Recommendations
Sponsors should consider establishing a DMC for trials with significant safety concerns.
Ensure DMC independence from sponsors to maintain objectivity.
Limit DMC use to trials where they are most beneficial due to added complexity.
Clearly define roles and responsibilities of all parties involved in trial monitoring.
Develop procedures to assess and manage potential conflicts of interest for DMC members.

Regulatory Considerations
Compliance with FDA regulations on adverse event reporting under 21 CFR 312.32 and 812.150.
Adherence to confidentiality protocols for unblinded data as per 21 CFR 314.126(b)(5).
Use of DMC recommendations to inform protocol changes while minimizing potential bias.
Maintenance of detailed records for DMC meetings and interim analyses for regulatory audits.
Engagement with FDA on early termination of trials or significant protocol changes due to safety concerns.

Findings
Medical devices using OTS software are vulnerable to cybersecurity threats, which can compromise safety and effectiveness.
FDA emphasizes that most software patches can be applied without prior approval unless they alter the device’s intended use or compromise safety and effectiveness.
Manufacturers must validate software changes to ensure they meet user needs and function as intended, following Quality System regulation.
Healthcare organizations rarely possess sufficient technical resources to independently manage medical device software, relying on manufacturers for updates and guidance.
Collaboration between healthcare organizations and manufacturers is critical for developing and implementing cybersecurity plans.

Recommendations
Manufacturers should monitor sources of quality data to identify vulnerabilities and implement corrective actions to maintain device safety and effectiveness.
Validate all software patches and changes, documenting that they meet user needs and functional requirements.
Develop and follow plans for managing software changes, including timelines, testing protocols, and communication strategies.
Healthcare organizations should collaborate with manufacturers to implement cybersecurity measures and address vulnerabilities.
Avoid applying third-party software patches to medical devices without guidance from the device manufacturer.

Regulatory Considerations
Manufacturers must comply with FDA’s Quality System regulation, ensuring that software patches and changes are validated and documented.
FDA approval is required for software changes that alter the device’s intended use or significantly affect its safety and effectiveness.
Healthcare organizations should not independently apply software patches but rely on manufacturer guidance to ensure compliance with FDA regulations.
Manufacturers should maintain a plan for managing cybersecurity vulnerabilities, including monitoring for threats and updating devices as needed.

Findings
High percentage of medical device recalls due to software failures.
Need for comprehensive software validation processes.
Importance of integrating software life cycle management with risk management.
Flexibility in applying validation principles while ensuring compliance.
Critical role of software validation in assuring quality and reducing recalls.

Recommendations
Develop a comprehensive validation plan, integrating software life cycle and risk management activities.
Document all software requirements and specifications to ensure traceability and validation.
Implement defect prevention measures throughout the development process, rather than relying solely on post-development testing.
Conduct thorough regression analysis and testing following any software change, including small updates.
Validate off-the-shelf software by leveraging vendor documentation, auditing vendor practices, or conducting system-level testing as necessary.

Regulatory Considerations
Adherence to Quality System Regulation (21 CFR Part 820), including specific software validation requirements under §820.70(i).
Compliance with Electronic Records; Electronic Signatures regulation (21 CFR Part 11) for systems managing electronic records and signatures.
Validation of automated systems for production and quality management, including tools for software design and testing.
Maintenance of documentation for validation protocols, test results, and system configurations to support FDA inspections.
Addressing validation requirements for all software, including components developed in-house, off-the-shelf software, and contractor-developed systems.

Findings
Significant changes to device design, basic principles of operation, or clinical protocols require prior FDA approval through an IDE supplement.
Developmental changes made in response to information gathered during a clinical investigation and minor protocol modifications may be implemented with a 5-day notice if they meet specified criteria.
Changes that do not affect the scientific soundness of the investigational plan, risk-benefit profile, or participant rights and safety can be reported in an IDE annual progress report.
Sponsors are responsible for conducting risk analyses and using credible information, such as design controls or peer-reviewed literature, to justify changes.
The FDA reserves the right to question the appropriateness of changes implemented without prior approval.

Recommendations
Conduct a risk analysis for any device or protocol change and ensure no new risks are introduced.
Use credible information, such as design control data, preclinical testing, or published literature, to assess the impact of proposed changes.
Submit IDE supplements for significant design or protocol changes that affect the validity of study data, participant safety, or investigational plan soundness.
Use the 5-day notice process for developmental changes that improve safety or effectiveness but do not represent significant design changes.
Report minor investigational plan changes, such as clarifying instructions or updating IRB information, in the IDE annual progress report.

Regulatory Considerations
IDE Supplements: Required for significant changes to device design, manufacturing processes, or protocols that may impact study data validity, risk-benefit analysis, or participant safety.
5-Day Notices: Applicable for developmental changes and protocol modifications that do not introduce new risks or affect study soundness.
Annual Progress Reports: Used for minor changes, including clarifications to instructions for use or informed consent materials, provided they do not affect participant safety or study data integrity.
FDA reserves the right to reclassify changes implemented under a 5-day notice or annual report if they determine the changes required prior approval.